APO Research
Talk to an analyst

APO RESEARCH · REPORT

Single-target Anti-VEGF Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Single-target Anti-VEGF Drugs Market Outlook and Growth Opportunities 2026

27 December 2025195 pages

Choose your research edition.

Industry ResearchSingle-target Anti-VEGF Drugs Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Single-target Anti-VEGF Drugs Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Single-target Anti-VEGF Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Single-target Anti-VEGF Drugs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Single-target Anti-VEGF Drugs Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Single-target Anti-VEGF Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Single-target Anti-VEGF Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Single-target Anti-VEGF Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Single-target Anti-VEGF Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Single-target Anti-VEGF Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Single-target Anti-VEGF Drugs market include Roche, Chengdu Kanghong Pharmaceutical, Samsung Bioepis, Regeneron Pharmaceuticals, Novartis, Coherus BioSciences and Biocon Biologics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Single-target Anti-VEGF Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Single-target Anti-VEGF Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Single-target Anti-VEGF Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Single-target Anti-VEGF Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Single-target Anti-VEGF Drugs Segment by Company

Roche

Chengdu Kanghong Pharmaceutical

Samsung Bioepis

Regeneron Pharmaceuticals

Novartis

Coherus BioSciences

Biocon Biologics

Single-target Anti-VEGF Drugs Segment by Type

Ranibizumab

Conbercept

Faricimab

Brolucizumab

Aflibercept

Other

Single-target Anti-VEGF Drugs Segment by Application

Diabetic Retinopathy

Age-related Macular Degeneration

Other

Single-target Anti-VEGF Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Single-target Anti-VEGF Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Single-target Anti-VEGF Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Single-target Anti-VEGF Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Single-target Anti-VEGF Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Single-target Anti-VEGF Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Single-target Anti-VEGF Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Single-target Anti-VEGF Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Single-target Anti-VEGF Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Single-target Anti-VEGF Drugs industry.

Chapter 3: Detailed analysis of Single-target Anti-VEGF Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Single-target Anti-VEGF Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Single-target Anti-VEGF Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Single-target Anti-VEGF Drugs Industry Trends Table 2. Single-target Anti-VEGF Drugs Industry Drivers Table 3. Single-target Anti-VEGF Drugs Industry Opportunities and Challenges Table 4. Single-target Anti-VEGF Drugs Industry Restraints Table 5. Global Single-target Anti-VEGF Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Single-target Anti-VEGF Drugs Revenue Share by Company (2021-2026) Table 7. Global Single-target Anti-VEGF Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Single-target Anti-VEGF Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Single-target Anti-VEGF Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Single-target Anti-VEGF Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Single-target Anti-VEGF Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Single-target Anti-VEGF Drugs Company, Product Type & Application Table 13. Global Single-target Anti-VEGF Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Single-target Anti-VEGF Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Ranibizumab Table 18. Significant Companies of Conbercept Table 19. Significant Companies of Faricimab Table 20. Significant Companies of Brolucizumab Table 21. Significant Companies of Aflibercept Table 22. Significant Companies of Other Table 23. Global Single-target Anti-VEGF Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Single-target Anti-VEGF Drugs Sales Volume by Type (2021-2026) & (K Units) Table 25. Global Single-target Anti-VEGF Drugs Sales Volume by Type (2027-2032) & (K Units) Table 26. Global Single-target Anti-VEGF Drugs Sales Volume Share by Type (2021-2026) Table 27. Global Single-target Anti-VEGF Drugs Sales Volume Share by Type (2027-2032) Table 28. Global Single-target Anti-VEGF Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Single-target Anti-VEGF Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Single-target Anti-VEGF Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Single-target Anti-VEGF Drugs Sales Value Share by Type (2021-2026) Table 32. Global Single-target Anti-VEGF Drugs Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Diabetic Retinopathy Table 34. Significant Companies of Age-related Macular Degeneration Table 35. Significant Companies of Other Table 36. Global Single-target Anti-VEGF Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Single-target Anti-VEGF Drugs Sales Volume by Application (2021-2026) & (K Units) Table 38. Global Single-target Anti-VEGF Drugs Sales Volume by Application (2027-2032) & (K Units) Table 39. Global Single-target Anti-VEGF Drugs Sales Volume Share by Application (2021-2026) Table 40. Global Single-target Anti-VEGF Drugs Sales Volume Share by Application (2027-2032) Table 41. Global Single-target Anti-VEGF Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Single-target Anti-VEGF Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Single-target Anti-VEGF Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Single-target Anti-VEGF Drugs Sales Value Share by Application (2021-2026) Table 45. Global Single-target Anti-VEGF Drugs Sales Value Share by Application (2027-2032) Table 46. Global Single-target Anti-VEGF Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Single-target Anti-VEGF Drugs Sales by Region (2021-2026) & (K Units) Table 48. Global Single-target Anti-VEGF Drugs Sales Market Share by Region (2021-2026) Table 49. Global Single-target Anti-VEGF Drugs Sales by Region (2027-2032) & (K Units) Table 50. Global Single-target Anti-VEGF Drugs Sales Market Share by Region (2027-2032) Table 51. Global Single-target Anti-VEGF Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Single-target Anti-VEGF Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Single-target Anti-VEGF Drugs Sales Value Share by Region (2021-2026) Table 54. Global Single-target Anti-VEGF Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Single-target Anti-VEGF Drugs Sales Value Share by Region (2027-2032) Table 56. Global Single-target Anti-VEGF Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 57. Global Single-target Anti-VEGF Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 58. Global Single-target Anti-VEGF Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. Global Single-target Anti-VEGF Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Single-target Anti-VEGF Drugs Sales by Country (2021-2026) & (K Units) Table 61. Global Single-target Anti-VEGF Drugs Sales Market Share by Country (2021-2026) Table 62. Global Single-target Anti-VEGF Drugs Sales by Country (2027-2032) & (K Units) Table 63. Global Single-target Anti-VEGF Drugs Sales Market Share by Country (2027-2032) Table 64. Global Single-target Anti-VEGF Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Single-target Anti-VEGF Drugs Sales Value Market Share by Country (2021-2026) Table 66. Global Single-target Anti-VEGF Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Single-target Anti-VEGF Drugs Sales Value Market Share by Country (2027-2032) Table 68. Roche Company Information Table 69. Roche Business Overview Table 70. Roche Single-target Anti-VEGF Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Roche Single-target Anti-VEGF Drugs Product Portfolio Table 72. Roche Recent Development Table 73. Chengdu Kanghong Pharmaceutical Company Information Table 74. Chengdu Kanghong Pharmaceutical Business Overview Table 75. Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Product Portfolio Table 77. Chengdu Kanghong Pharmaceutical Recent Development Table 78. Samsung Bioepis Company Information Table 79. Samsung Bioepis Business Overview Table 80. Samsung Bioepis Single-target Anti-VEGF Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Samsung Bioepis Single-target Anti-VEGF Drugs Product Portfolio Table 82. Samsung Bioepis Recent Development Table 83. Regeneron Pharmaceuticals Company Information Table 84. Regeneron Pharmaceuticals Business Overview Table 85. Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Product Portfolio Table 87. Regeneron Pharmaceuticals Recent Development Table 88. Novartis Company Information Table 89. Novartis Business Overview Table 90. Novartis Single-target Anti-VEGF Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Novartis Single-target Anti-VEGF Drugs Product Portfolio Table 92. Novartis Recent Development Table 93. Coherus BioSciences Company Information Table 94. Coherus BioSciences Business Overview Table 95. Coherus BioSciences Single-target Anti-VEGF Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Coherus BioSciences Single-target Anti-VEGF Drugs Product Portfolio Table 97. Coherus BioSciences Recent Development Table 98. Biocon Biologics Company Information Table 99. Biocon Biologics Business Overview Table 100. Biocon Biologics Single-target Anti-VEGF Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Biocon Biologics Single-target Anti-VEGF Drugs Product Portfolio Table 102. Biocon Biologics Recent Development Table 103. Key Raw Materials Table 104. Raw Materials Key Suppliers Table 105. Single-target Anti-VEGF Drugs Distributors List Table 106. Single-target Anti-VEGF Drugs Customers List Table 107. Research Programs/Design for This Report Table 108. Authors List of This Report Table 109. Secondary Sources Table 110. Primary Sources List of Figures Figure 1. Single-target Anti-VEGF Drugs Product Image Figure 2. Global Single-target Anti-VEGF Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Single-target Anti-VEGF Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Single-target Anti-VEGF Drugs Sales (2021-2032) & (K Units) Figure 5. Global Single-target Anti-VEGF Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Single-target Anti-VEGF Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Ranibizumab Image Figure 10. Conbercept Image Figure 11. Faricimab Image Figure 12. Brolucizumab Image Figure 13. Aflibercept Image Figure 14. Other Image Figure 15. Global Single-target Anti-VEGF Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Single-target Anti-VEGF Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Single-target Anti-VEGF Drugs Sales Volume Share by Type (2021-2032) Figure 18. Global Single-target Anti-VEGF Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Single-target Anti-VEGF Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Single-target Anti-VEGF Drugs Sales Value Share by Type (2021-2032) Figure 21. Diabetic Retinopathy Image Figure 22. Age-related Macular Degeneration Image Figure 23. Other Image Figure 24. Global Single-target Anti-VEGF Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Single-target Anti-VEGF Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Single-target Anti-VEGF Drugs Sales Volume Share by Application (2021-2032) Figure 27. Global Single-target Anti-VEGF Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Single-target Anti-VEGF Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Single-target Anti-VEGF Drugs Sales Value Share by Application (2021-2032) Figure 30. Global Single-target Anti-VEGF Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 31. Global Single-target Anti-VEGF Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Single-target Anti-VEGF Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Single-target Anti-VEGF Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Single-target Anti-VEGF Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. North America Single-target Anti-VEGF Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Single-target Anti-VEGF Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Single-target Anti-VEGF Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Single-target Anti-VEGF Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Single-target Anti-VEGF Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Single-target Anti-VEGF Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. South America Single-target Anti-VEGF Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Single-target Anti-VEGF Drugs Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Single-target Anti-VEGF Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Single-target Anti-VEGF Drugs Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Single-target Anti-VEGF Drugs Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Ranibizumab
  • Conbercept
  • Faricimab
  • Brolucizumab
  • Aflibercept
  • Other
Applications
  • Diabetic Retinopathy
  • Age-related Macular Degeneration
  • Other
Companies covered
  • Roche
  • Chengdu Kanghong Pharmaceutical
  • Samsung Bioepis
  • Regeneron Pharmaceuticals
  • Novartis
  • Coherus BioSciences
  • Biocon Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Single-target Anti-VEGF Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Single-target Anti-VEGF Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Single-target Anti-VEGF Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Single-target Anti-VEGF Drugs Market Dynamics
  1. 2.1 Single-target Anti-VEGF Drugs Industry Trends
  2. 2.2 Single-target Anti-VEGF Drugs Industry Drivers
  3. 2.3 Single-target Anti-VEGF Drugs Industry Opportunities and Challenges
  4. 2.4 Single-target Anti-VEGF Drugs Industry Restraints
3 Single-target Anti-VEGF Drugs Market by Company
  1. 3.1 Global Single-target Anti-VEGF Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Single-target Anti-VEGF Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Single-target Anti-VEGF Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Single-target Anti-VEGF Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Single-target Anti-VEGF Drugs Company Ranking (2024-2026)
  6. 3.6 Global Single-target Anti-VEGF Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Single-target Anti-VEGF Drugs Company Product Type and Application
  8. 3.8 Global Single-target Anti-VEGF Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Single-target Anti-VEGF Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Single-target Anti-VEGF Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Single-target Anti-VEGF Drugs Market by Type
  1. 4.1 Single-target Anti-VEGF Drugs Type Introduction
  2. 4.1.1 Ranibizumab
  3. 4.1.2 Conbercept
  4. 4.1.3 Faricimab
  5. 4.1.4 Brolucizumab
  6. 4.1.5 Aflibercept
  7. 4.1.6 Other
  8. 4.2 Global Single-target Anti-VEGF Drugs Sales Volume by Type
  9. 4.2.1 Global Single-target Anti-VEGF Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Single-target Anti-VEGF Drugs Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Single-target Anti-VEGF Drugs Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Single-target Anti-VEGF Drugs Sales Value by Type
  13. 4.3.1 Global Single-target Anti-VEGF Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Single-target Anti-VEGF Drugs Sales Value by Type (2021-2032)
  15. 4.3.3 Global Single-target Anti-VEGF Drugs Sales Value Share by Type (2021-2032)
5 Single-target Anti-VEGF Drugs Market by Application
  1. 5.1 Single-target Anti-VEGF Drugs Application Introduction
  2. 5.1.1 Diabetic Retinopathy
  3. 5.1.2 Age-related Macular Degeneration
  4. 5.1.3 Other
  5. 5.2 Global Single-target Anti-VEGF Drugs Sales Volume by Application
  6. 5.2.1 Global Single-target Anti-VEGF Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Single-target Anti-VEGF Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Single-target Anti-VEGF Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Single-target Anti-VEGF Drugs Sales Value by Application
  10. 5.3.1 Global Single-target Anti-VEGF Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Single-target Anti-VEGF Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Single-target Anti-VEGF Drugs Sales Value Share by Application (2021-2032)
6 Single-target Anti-VEGF Drugs Regional Sales and Value Analysis
  1. 6.1 Global Single-target Anti-VEGF Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Single-target Anti-VEGF Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Single-target Anti-VEGF Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Single-target Anti-VEGF Drugs Sales by Region (2027-2032)
  5. 6.3 Global Single-target Anti-VEGF Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Single-target Anti-VEGF Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Single-target Anti-VEGF Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Single-target Anti-VEGF Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Single-target Anti-VEGF Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Single-target Anti-VEGF Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Single-target Anti-VEGF Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Single-target Anti-VEGF Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Single-target Anti-VEGF Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Single-target Anti-VEGF Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Single-target Anti-VEGF Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Single-target Anti-VEGF Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Single-target Anti-VEGF Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Single-target Anti-VEGF Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Single-target Anti-VEGF Drugs Sales Value Share by Country, 2025 VS 2032
7 Single-target Anti-VEGF Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Single-target Anti-VEGF Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Single-target Anti-VEGF Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Single-target Anti-VEGF Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Single-target Anti-VEGF Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Single-target Anti-VEGF Drugs Sales by Country (2027-2032)
  6. 7.4 Global Single-target Anti-VEGF Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Single-target Anti-VEGF Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Single-target Anti-VEGF Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Single-target Anti-VEGF Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Single-target Anti-VEGF Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Single-target Anti-VEGF Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Roche
  2. 8.1.1 Roche Company Information
  3. 8.1.2 Roche Business Overview
  4. 8.1.3 Roche Single-target Anti-VEGF Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Roche Single-target Anti-VEGF Drugs Product Portfolio
  6. 8.1.5 Roche Recent Developments
  7. 8.2 Chengdu Kanghong Pharmaceutical
  8. 8.2.1 Chengdu Kanghong Pharmaceutical Company Information
  9. 8.2.2 Chengdu Kanghong Pharmaceutical Business Overview
  10. 8.2.3 Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Product Portfolio
  12. 8.2.5 Chengdu Kanghong Pharmaceutical Recent Developments
  13. 8.3 Samsung Bioepis
  14. 8.3.1 Samsung Bioepis Company Information
  15. 8.3.2 Samsung Bioepis Business Overview
  16. 8.3.3 Samsung Bioepis Single-target Anti-VEGF Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Samsung Bioepis Single-target Anti-VEGF Drugs Product Portfolio
  18. 8.3.5 Samsung Bioepis Recent Developments
  19. 8.4 Regeneron Pharmaceuticals
  20. 8.4.1 Regeneron Pharmaceuticals Company Information
  21. 8.4.2 Regeneron Pharmaceuticals Business Overview
  22. 8.4.3 Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Product Portfolio
  24. 8.4.5 Regeneron Pharmaceuticals Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Single-target Anti-VEGF Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Single-target Anti-VEGF Drugs Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Coherus BioSciences
  32. 8.6.1 Coherus BioSciences Company Information
  33. 8.6.2 Coherus BioSciences Business Overview
  34. 8.6.3 Coherus BioSciences Single-target Anti-VEGF Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Coherus BioSciences Single-target Anti-VEGF Drugs Product Portfolio
  36. 8.6.5 Coherus BioSciences Recent Developments
  37. 8.7 Biocon Biologics
  38. 8.7.1 Biocon Biologics Company Information
  39. 8.7.2 Biocon Biologics Business Overview
  40. 8.7.3 Biocon Biologics Single-target Anti-VEGF Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Biocon Biologics Single-target Anti-VEGF Drugs Product Portfolio
  42. 8.7.5 Biocon Biologics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Single-target Anti-VEGF Drugs Value Chain Analysis
  2. 9.1.1 Single-target Anti-VEGF Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Single-target Anti-VEGF Drugs Sales Mode & Process
  6. 9.2 Single-target Anti-VEGF Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Single-target Anti-VEGF Drugs Distributors
  9. 9.2.3 Single-target Anti-VEGF Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst